Veenat 100mg

Veenat 100 mg is an antitumor remedy, an inhibitor of protein tyrosine kinase, an abnormal enzyme that is produced by the Philadelphia chromosome in chronic myelogenous leukemia.

The active substance of the preparation is Imatinib induces apodosis of Bcr-Abl-positive tumor cells and suppresses their proliferation. Does not have selectivity. It is used for the treatment of chronic myelogenous leukemia, chronic eosinophilic leukemia, hypereosinophilic syndrome, myeloproliferative and myelodysplastic diseases, etc.

Treatment should be done under the supervision of a doctor.

Indications for using.

Pharmaceutical antitumor remedy Veenat 100 mg is intended for therapy:
chronic myelogenous leukemia (chronic phase, accelerated phase, blast crisis), if previous interferon Alfa therapy failed;
first diagnosed acute lymphoblastic leukemia (in adults);
myeloproliferative and myelodysplastic diseases;
chronic eosinophilic leukemia;
systemic mastocytosis (in adults);
hypereosinophilic syndrome;
metastatic and inoperable malignant stromal GIT-tumors;
recurrent, metastatic, inoperable swelling dermatofibrosarcoma (in adults).

Contraindications.

An antitumor agent is not recommended for persons with increased susceptibility (of an individual nature) to Imatinib or to supplementary components of the remedy.
In addition, do not use Veenat 100 mg during pregnancy and lactation, as well as to treat children under 2 years.
The acute using of Veenat 100 mg is necessary for persons with chronic cardiac and hepatic insufficiency.

Side effects.

As side effects of the using of Veenat 100 mg are:
pancytopenia, anemia, with some probability – neutropenia and thrombocytopenia;
hyperbilirubinemia, excessive activity of alkaline phosphatase, hepatic transaminases, vomiting, nausea;
impaired kidney function, fluid retention in the body, leading to increased body mass, swelling of the peri-orbital area, somewhat less often – limbs, superficial edema, pulmonary edema, common, local edema, ascites, pericardial, pleural effusion;
possible heart failure of chronic course;
muscle spasm.

With prolonged Veenat 100 mg therapy, there is a risk of developing nephro- and hepatotoxicity, as well as opportunistic infections.
An experiment using a daily dose of 3600 mg / m 2 (which exceeds the maximum dose by 7.5 times) for 7-10 days resulted in the death of experimental animals due to multiple degenerative changes in organs and tissues.

Precautions for admission.

The active ingredient Imatinib can provoke irritation of the gastrointestinal tract, for this reason it is recommended to take the drug with food, washing down with a glass of water.